Origin Therapeutics’ portfolio company, Xpira Pharmaceuticals, has received FDA approval for its Psilocybin Trial IND Application.
University of Cincinnati postdoctoral researcher Neşe Devenot has stated that the field of psychedelics is fraught with ethical concerns and financial interests.
Revive Therapeutics has announced that it is working on its first Phase I/II clinical study to evaluate oral psilocybin in the treatment of methamphetamine use disorder.
Drug discovery and development company Mindset Pharma has filed for national patents protecting “Family 1” – second-generation psilocybin analogues – in 16 different countries, including South...
Awakn Life Sciences has signed the twelve month option agreement with a drug development company that will see its ketamine formulation and route of administration optimised...
Awakn Life Sciences has signed its first licensing partnership agreement in Canada with Ontario-based Wellbeings Pain Management and Dependency Clinic, which is focused on multi-disciplinary, evidence-based,...
Optimi Health has received approval from Health Canada to manufacture and distribute psychedelic medicines.
UK-based Small Pharma has announced that its DMT patent strategy has been strengthened with a new US patent protection on injectable DMT delivery in its lead...
InsightAce Analytic has projected that the global psychedelic therapeutics market, valued at US$3.61bn in 2021, is expected to reach US$8.31bn (~£6.92bn) by 2028.
PsiloTec Health Solutions Inc.,